Santosh Vetticaden, MD, PhD, MBA

As part of the Inflation Reduction Act’s (#IRA) first round of #Medicare negotiations, the Biden administration has announced significant price reductions on 10 high-cost #prescriptiondrugs. Set to go into effect in 2026, these cuts will range from 38% to 79%, impacting major treatments for #diabetes, #heartfailure, and #autoimmunediseases in an effort to lower healthcare costs for #Medicarepatients. While the administration celebrates the potential savings for Americans, the #pharmaceuticalindustry argues that the changes may do more harm to patients by limiting access to treatments and stifling innovation. The ongoing debate highlights the complex balance between affordability with the availability of new treatments. 

9

1 Comment

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

Over the past year, I've had the privilege of attending numerous conferences and networking with investors and executives in the biotech industry. It's evident that securing funding in the current climate has been challenging. However, one consistent theme in my conversations with investors is the crucial importance of a strong and preferably experienced leadership team. Companies cannot just rely on exceptional science; they need the ability to articulate a commercial strategy, a clear vision, and strong operational expertise. This will make them attractive to investors looking for reliable and innovative partners in the high-risk biotech sector. A prime example is Third Arc Bio, which recently raised $165 million to develop oncology and autoimmune biologics. Their success can be attributed not only to their innovative science but also to their exceptional leadership team, led by former Johnson & Johnson executives. This underscores the critical role that experienced leadership plays in gaining investor confidence and driving biotech innovation forward. At GENerX Life, we are actively working with clients worldwide, coaching and advising on the leadership, skills, and competencies required to attract investment. Our expertise ensures that biotech companies are equipped with the right leaders and infrastructure to navigate today's competitive landscape. https://lnkd.in/eTi_TMyJ Visit us to learn more about our services - www.generx.life #Biotech #Leadership #Funding #Innovation #ExecutiveSearch #BiotechFunding #BusinessGrowth #GENerXLife #BiotechLeaders #Agileleaders

7

1 Comment